Fresenius SE & Co. KGaA Price & Performance (FSNUY)

Short interest in Fresenius SE & Co. KGaA declined by nearly 45% in March, signaling reduced bearish bets. The company’s stock recently hit a 12-month high, reflecting growing investor confidence. Analysts have maintained a positive outlook, and the firm’s leverage and liquidity ratios remain healthy, supporting its upward momentum.123

Fresenius has completed its transformation phase, posting high single-digit organic revenue growth and double-digit EBIT and EPS increases for 2024. Strategic divestments and a focus on core platforms have strengthened its balance sheet, leading to a proposed dividend hike and an optimistic outlook for 2025 as the company enters its next growth stage.14

Investor sentiment toward Fresenius SE & Co. KGaA has turned more favorable this week, buoyed by recent operational streamlining and portfolio adjustments. The company’s focus on its core businesses, coupled with solid financial performance, has contributed to a notable rise in its share price, highlighting renewed confidence in the healthcare group’s direction.56